iRhythm Technologies competitors

Shai Gozani, founded NeuroMetrix, Inc. in 1996 as a spin-off from the Massachusetts Institute of Technology. He currently serves as Chairman of the board of directors and as our President and Chief Executive Officer. Shai has led the Company from a venture capital backed start-up, through an initial public offering on Nasdaq, through development of a successful diagnostics business, and presently into the wearable technology sector. Over 2.5 million patients have benefited from the Company’s technology over the past 17 years.Shai has published over 30 peer-reviewed scientific articles and has been awarded over 40 US and international patents. He holds a B.A. degree in Computer Science, a M.S. degree in Electrical Engineering & Computer Science (Biomedical Engineering Focus) and a Ph.D. in Neurobiology, from the University of California, Berkeley. Shai also received an M.D. from Harvard Medical School and the Harvard-MIT Division of Health Sciences and Technology at M.I.T.

President/CEO with proven track record of value creation and consistently delivering outstanding results amid challenging situations. Combines strong strategic mindset with a relentless focus on execution. Committed to developing high-performing teams and a winning culture. Experienced in leading capital equipment, disposables, and implantables businesses within public and private equity capital structures. Have transformed businesses and sold to strategic acquirers at attractive valuations.

Matthew Call is a Chief Executive Officer at Photomedex.

Mr. Roman joined Acutus with over 15 years of experience in the medical technology industry. Most recently, Mr. Roman served as Vice President, Strategy and FP&A for Baxter International, Inc., where Mr. Roman has held roles of increasing responsibility since 2016. Prior to joining Baxter, Mr. Roman was a managing director at Goldman, Sachs & Co., leading the firm’s US medical technology equity research team. Mr. Roman began his professional career in 2004 at Morgan Stanley, where he also covered the medical technology sector as a research analyst.